Zydus files IND application for dyslipidemia compound
This article was originally published in Scrip
Zydus Cadilahas filed an IND for a lipid lowering molecule with the Drugs Controller General of India. The company claims that the new compound, ZYT1, may provide an alternative to statins or be an add-on to statin therapy. In preclinical studies, ZYT1 has shown a beneficial effect on LDL-cholesterol and triglycerides, compared with the effects seen with statins. When combined with statins, ZYT1 has shown a "pronounced effect" in lowering LDL-cholesterol and triglycerides and has a very high margin of safety, Zydus said. The company now has six compounds in various stages of clinical development, with two candidates in advanced Phase II. The company's R&D is focused on the metabolic, cardiovascular and inflammation segments.